{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T19:13:13Z","timestamp":1783710793149,"version":"3.55.0"},"reference-count":26,"publisher":"Xia & He Publishing","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["gene expr"],"published-print":{"date-parts":[[2018,3,21]]},"abstract":"<jats:p>The first NS3\/4A hepatitis C virus (HCV) protease inhibitors telaprevir and boceprevir were approved in 2011, and both NS5A and NS5B polymerase inhibitors were launched. Recently, direct-acting antivirals (DAAs) have had a major impact on patients infected with HCV. HCV DAAs are highly\n effective antivirals with fewer side effects. DAAs have been developed for the treatment of HCV infection in combination with PEG-IFN-\u03b1\/RBV as well as in IFN-free regimens. However, some drug resistance mutations occur when a single oral DAA is used for treatment, which indicates that\n there is a low-frequency drug resistance mutation in HCV patients before the application of antiviral drugs. Our research showed that natural resistance to HCV DAAs was found in treatment-naive CHC patients and that the drug resistance mutation rates differ in various HCV genotypes. Many challenges\n posed by natural resistance should be considered in the context of DAA therapies.<\/jats:p>","DOI":"10.3727\/105221617x15100607143377","type":"journal-article","created":{"date-parts":[[2017,12,8]],"date-time":"2017-12-08T20:07:55Z","timestamp":1512763675000},"page":"63-69","source":"Crossref","is-referenced-by-count":10,"title":["Analysis of Naturally Occurring Resistance-Associated Variants to NS3\/4A Protein Inhibitors, NS5A Protein Inhibitors, and NS5B Polymerase Inhibitors in Patients With Chronic Hepatitis C"],"prefix":"10.14218","volume":"18","author":[{"given":"Danhui","family":"Sun","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingjia","family":"Dai","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuebing","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"5334","reference":[{"issue":"4","key":"b1","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1002\/hep.26141","article-title":"Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence","volume":"57","year":"2013","journal-title":"Hepatology"},{"key":"b2","series-title":"Current Topics in Microbiology and Immunology","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/978-3-642-27340-7_5","article-title":"Hepatitis C virus proteins: From structure to function","volume-title":"Hepatitis C virus: From molecular virology to antiviral therapy","volume":"vol. 369","year":"2013"},{"issue":"Part 11","key":"b3","first-page":"2391","article-title":"Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region","volume":"74","year":"1993","journal-title":"J Gen Virol."},{"key":"b4","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/hep.26744","article-title":"Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: Updated criteria and genotype assignment web resource","volume":"59","year":"2014","journal-title":"Hepatology"},{"issue":"4","key":"b5","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1002\/hep.20819","article-title":"Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes","volume":"42","year":"2005","journal-title":"Hepatology"},{"issue":"2","key":"b6","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jhep.2011.02.023","article-title":"EASL clinical practice guidelines: Management of hepatitis C virus infection","volume":"55","year":"2011","journal-title":"J Hepatol."},{"issue":"8","key":"b7","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1093\/jac\/dkr215","article-title":"Directly acting antivirals against hepatitis C virus","volume":"66","year":"2011","journal-title":"J Antimicrob Chemother."},{"key":"b8","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1128\/AAC.00863-07","article-title":"Phenotypic characterization of resistant Val36 variants of hepatitis C virus NS3-4A serine protease","volume":"52","year":"2008","journal-title":"Antimicrob Agents Chemother."},{"issue":"5","key":"b9","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1128\/AAC.01452-09","article-title":"In vitro resistance profile of the hepatitis C virus NS3\/4A protease inhibitor TMC435","volume":"54","year":"2010","journal-title":"Antimicrob Agents Chemother."},{"issue":"8","key":"b10","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1517\/13543784.2012.690392","article-title":"TMC435 for the treatment of chronic hepatitis C","volume":"21","year":"2012","journal-title":"Expert Opin Investig Drugs"},{"key":"b11","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/S0168-8278(11)60013-5","article-title":"Impact of IL23B genotype and pretreatment serum IP-10 in treatment-na\u00efve genotype-1 HCV patients treated with TMC435 in combination with peginterferon a-2A and ribavirin in PILLAR study","volume":"54","year":"2011","journal-title":"J Hepatol."},{"key":"b12","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1128\/AAC.04226-14","article-title":"In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A","volume":"59","year":"2015","journal-title":"Antimicrob Agents Chemother."},{"key":"b13","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1186\/1743-422X-10-355","article-title":"Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-na\u00efve patients","volume":"10","year":"2013","journal-title":"Virol J."},{"key":"b14","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1128\/AAC.00556-10","article-title":"Resistance analysis of the HCV NS5A inhibitors BMS-790052, in the in vitro replicon system","volume":"54","year":"2010","journal-title":"Antimicrob Agents Chemother."},{"key":"b15","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1002\/hep.24594","article-title":"Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein NS5A replication complex inhibitor BMS-790052 in humans: In vitro and in vivo correlations","volume":"54","year":"2011","journal-title":"Hepatology"},{"key":"b16","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0168-8278(12)60016-6","article-title":"TMC435 in HCV genotype 1 patients who have failed previous pegylated interferon\/ribavirin treatment: Final SVR24 results of the ASPIRE trial","volume":"56","year":"2012","journal-title":"J Hepatol."},{"issue":"4","key":"b17","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.jcv.2012.04.024","article-title":"Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b","volume":"54","year":"2012","journal-title":"J Clin Virol."},{"issue":"2","key":"b18","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jhep.2015.09.011","article-title":"The importance of resistance to direct antiviral drugs in HCV infection in clinical practice","volume":"64","year":"2016","journal-title":"J Hepatol."},{"key":"b19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.virol.2014.12.037","article-title":"Next generation sequencing of the hepatitis C virus NS5B gene reveals potential novel S282 drug resistance mutations","volume":"477","year":"2015","journal-title":"Virology"},{"issue":"1","key":"b20","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/hep.27375","article-title":"Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir","volume":"61","year":"2015","journal-title":"Hepatology"},{"key":"b21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.virol.2014.12.037","article-title":"Next generation sequencing of the hepatitis C virus NS5B gene reveals potential novel S282 drug resistance mutations","volume":"477","year":"2015","journal-title":"Virology"},{"key":"b22","first-page":"3359","article-title":"Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus","volume":"10","year":"2012","journal-title":"Antimicrob Agents Chemother."},{"key":"b23","first-page":"611","article-title":"The HCV NS5B nucleoside and non-nucleoside inhibitors","volume":"10","year":"2011","journal-title":"Clin Liver Dis."},{"key":"b24","first-page":"1164A","article-title":"In vitro studies demonstrate that combinations of antiviral agents that include HCV polymerase inhibitor ANA598 have the potential to overcome viral resistance","volume":"48","year":"2008","journal-title":"Hepatology"},{"issue":"4","key":"b25","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.jhep.2012.11.012","article-title":"Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir","volume":"58","year":"2013","journal-title":"J Hepatol."},{"key":"b26","first-page":"1544","article-title":"Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment","volume":"10","year":"2013","journal-title":"J Virol."}],"container-title":["Gene Expression"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/cog\/ge\/2018\/00000018\/00000001\/art00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T18:16:58Z","timestamp":1783707418000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.3727\/105221617X15100607143377"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,21]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,3,21]]}},"alternative-id":["1052-2166(20180321)18:1L.63;1-"],"URL":"https:\/\/doi.org\/10.3727\/105221617x15100607143377","relation":{},"ISSN":["1052-2166"],"issn-type":[{"value":"1052-2166","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3,21]]}}}